Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY

v3.22.4
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Preferred Stock
Common Stock
Additional Paid-in- Capital
Treasury Stock
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Total
Beginning balance at Dec. 28, 2019 $ 3 $ 38 $ 187,147 $ (7,146) $ 214 $ (167,876) $ 12,380
Beginning balance (in shares) at Dec. 28, 2019 2,771 36,167          
Increase (Decrease) in Stockholders' Equity              
Net income (loss)           (1,513) (1,513)
Issuance of common stock, net of underwriters' offering expenses and commissions   $ 5 60,456       60,461
Issuance of common stock, net of underwriters' offering expenses and commissions (in shares)   4,900          
Issuance of shares in connection with stock option exercise   $ 3 3,703       3,706
Issuance of shares in connection with stock option exercise (in shares)   2,200          
Issuance of shares in connection with restricted stock units vesting   $ 2 457       459
Issuance of shares in connection with restricted stock units vesting (in shares)   2,000          
Issuance of shares in connection with BOD Fees     22       22
Issuance of shares in connection with BOD Fees (in shares)   8          
Share-based compensation     8,437       8,437
Dividends on preferred stock     38     (72) (34)
Dividends on preferred stock (in shares)   45          
Conversion of preferred stock $ (3) $ 3          
Conversion of preferred stock (in shares) (2,771) 2,771          
Actuarial gain (loss) on defined benefit plan         (400)   (400)
Unrealized gain (loss) on deferred compensation trust assets         57   57
Effect of changes in foreign currencies         (86)   (86)
Ending balance at Jan. 02, 2021   $ 51 260,260 (7,146) (215) (169,461) 83,489
Ending balance (in shares) at Jan. 02, 2021   48,091          
Increase (Decrease) in Stockholders' Equity              
Net income (loss)           (10,339) (10,339)
Issuance of shares in connection with stock option exercise   $ 2 3,659       $ 3,661
Issuance of shares in connection with stock option exercise (in shares)   2,060         2,060,000
Issuance of shares in connection with restricted stock units vesting   $ 3 986       $ 989
Issuance of shares in connection with restricted stock units vesting (in shares)   2,665          
Issuance of stock awards     778       778
Issuance of stock awards (in shares)   143          
Issuance of shares in connection with BOD Fees     23       23
Issuance of shares in connection with BOD Fees (in shares)   1          
Registration costs - common stock     (68)       (68)
Officers and directors stock purchase plan     4       4
Share-based compensation     17,066       17,066
Stock repurchase     (45) (479)     (524)
Actuarial gain (loss) on defined benefit plan         307   307
Unrealized gain (loss) on deferred compensation trust assets         89   89
Effect of changes in foreign currencies         93   93
Ending balance at Jan. 01, 2022   $ 56 282,663 (7,625) 274 (179,800) 95,568
Ending balance (in shares) at Jan. 01, 2022   52,960          
Increase (Decrease) in Stockholders' Equity              
Net income (loss)           (951) (951)
Issuance of shares in connection with stock option exercise     1,284       $ 1,284
Issuance of shares in connection with stock option exercise (in shares)   738         738,000
Issuance of shares in connection with restricted stock units vesting   $ 1 (1)        
Issuance of shares in connection with restricted stock units vesting (in shares)   872          
Issuance of stock awards to consultants     81       $ 81
Issuance of stock awards to consultants (in shares)   10          
Issuance of shares in connection with BOD Fees     22       22
Issuance of shares in connection with BOD Fees (in shares)   3          
Issuance of shares in connection with ESPP     795       795
Issuance of shares in connection with ESPP (in shares)   107          
Officers and directors stock purchase plan     26       26
Officers and directors stock purchase plan (in shares)   3          
Share-based compensation     12,395       12,395
Stock repurchase       0      
Actuarial gain (loss) on defined benefit plan         872   872
Unrealized gain (loss) on deferred compensation trust assets         (147)   (147)
Effect of changes in foreign currencies         127   127
Ending balance at Dec. 31, 2022   $ 57 $ 297,265 $ (7,625) $ 1,126 $ (180,751) $ 110,072
Ending balance (in shares) at Dec. 31, 2022   54,693